Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.465 SEK 0.45%
Market Cap: 518.1m SEK

Relative Value

There is not enough data to reliably calculate the relative value of ACE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
6.1
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-15.8
Industry
23.6
Forward
-36.8
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-15.1
Industry
20.2
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-16.4
Industry
22.9
vs History
68
vs Industry
26
Median 3Y
9.2
Median 5Y
9.9
Industry
2.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
Forward
5.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-14.6
Industry
4.9
Forward
29.2
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-14.6
Industry
4.9
Forward
29.2
vs History
vs Industry
Median 3Y
-8
Median 5Y
-13.9
Industry
5.4
vs History
vs Industry
Median 3Y
-8
Median 5Y
-13.9
Industry
4
vs History
73
vs Industry
37
Median 3Y
15.7
Median 5Y
26.4
Industry
5.1

Multiples Across Competitors

ACE Competitors Multiples
Ascelia Pharma AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Ascelia Pharma AB
STO:ACE
518.1m SEK 0 -6.1 -6.5 -6.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 139 238 -162 258.7 -197 033.9 -194 785.5
US
Abbvie Inc
NYSE:ABBV
338.1B USD 5.9 81.4 15.5 22.9
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
135.5B USD 4.7 22.7 9.9 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD 10.7 -120.4 25.6 26.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 063.6 -526.6 -573.4 -558.1
AU
CSL Ltd
ASX:CSL
124.4B AUD 5.3 29.4 18.1 22.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.5B USD 4.2 13.2 11.8 13.3
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61 -65.7 -59.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.3B USD 18 -156.9 -704 -352.8
P/S Multiple
Revenue Growth P/S to Growth
SE
Ascelia Pharma AB
STO:ACE
Average P/S: 3 414 137.5
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 139 238
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.7
10%
1.1
US
E
Epizyme Inc
F:EPE
2 063.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18
30%
0.6
P/E Multiple
Earnings Growth PEG
SE
Ascelia Pharma AB
STO:ACE
Average P/E: 34.8
Negative Multiple: -6.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 258.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.7
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -120.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.6 N/A N/A
AU
CSL Ltd
ASX:CSL
29.4
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -156.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Ascelia Pharma AB
STO:ACE
Average EV/EBITDA: 15.9
Negative Multiple: -6.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 033.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.4 N/A N/A
AU
CSL Ltd
ASX:CSL
18.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -704 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Ascelia Pharma AB
STO:ACE
Average EV/EBIT: 20.5
Negative Multiple: -6.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 785.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.1 N/A N/A
AU
CSL Ltd
ASX:CSL
22.6
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -352.8 N/A N/A